09:58 AM EDT, 05/24/2024 (MT Newswires) -- CG Oncology ( CGON ) said Friday that its phase 2 trial of cretostimogene plus pembrolizumab to treat BCG-unresponsive high-risk non-muscle invasive bladder cancer with carcinoma in situ met its primary endpoint.

Final data from the phase 2 trial showed a "class-leading" complete response and duration of response compared with existing and other investigation therapies, with a 54% complete response rate at 24 months as of May 17, according to the company.

The results reinforce a "potential use of cretostimogene as a bladder-sparing backbone therapy" for bladder cancer, the company said.

Cretostimogene was also generally well-tolerated by patients either as monotherapy or in combination, the company added.

The results of the trial will be presented at the annual meeting of the American Society of Clinical Oncology, which is taking place on May 31 to June 4 in Chicago, CG Oncology ( CGON ) said.

Price: 30.00, Change: +0.01, Percent Change: +0.03